Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
252.73
-3.23 (-1.26%)
Nov 20, 2026, 4:00 PM EST - Market closed
Ascendis Pharma Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Ascendis Pharma stock has a consensus rating of "Strong Buy" and an average price target of $315.26. The average 1-year stock price forecast is 24.74% higher than the current stock price, while the lowest is $272.13 (+7.68%) and the highest is $354.32 (+40.20%).
Price Target: $315.26 (+24.74%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 16 | 15 | 15 | 15 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Maintains $330 → $335 | Buy | Maintains | $330 → $335 | +32.55% | Nov 16, 2026 |
| Barclays | Barclays | Buy Maintains $329 → $341 | Buy | Maintains | $329 → $341 | +34.93% | Nov 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $290 | Buy | Maintains | $290 | +14.75% | Nov 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $326 | Buy | Reiterates | $326 | +28.99% | Nov 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $304 | Buy | Reiterates | $304 | +20.29% | Nov 13, 2026 |
Financial Forecast
Revenue This Year
1.38B
from 720.13M
Increased by 91.55%
Revenue Next Year
2.02B
from 1.38B
Increased by 46.52%
EPS This Year
15.98
EPS Next Year
10.78
from 15.98
Decreased by -32.55%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.